Ardelyx Inc (ARDX)
7.815
+0.02
(+0.32%)
USD |
NASDAQ |
May 17, 16:00
7.815
0.00 (0.00%)
After-Hours: 20:00
Ardelyx Research and Development Expense (Quarterly): 10.58M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 10.58M |
| December 31, 2023 | 9.524M |
| September 30, 2023 | 8.637M |
| June 30, 2023 | 8.282M |
| March 31, 2023 | 9.093M |
| December 31, 2022 | 9.142M |
| September 30, 2022 | 7.467M |
| June 30, 2022 | 9.741M |
| March 31, 2022 | 8.851M |
| December 31, 2021 | 20.97M |
| September 30, 2021 | 23.70M |
| June 30, 2021 | 26.02M |
| March 31, 2021 | 20.46M |
| December 31, 2020 | 18.10M |
| September 30, 2020 | 12.24M |
| June 30, 2020 | 18.86M |
| March 31, 2020 | 15.84M |
| December 31, 2019 | 14.24M |
| September 30, 2019 | 17.58M |
| June 30, 2019 | 19.48M |
| March 31, 2019 | 20.38M |
| December 31, 2018 | 22.04M |
| September 30, 2018 | 17.94M |
| Date | Value |
|---|---|
| June 30, 2018 | 16.05M |
| March 31, 2018 | 13.35M |
| December 31, 2017 | 17.16M |
| September 30, 2017 | 15.36M |
| June 30, 2017 | 20.57M |
| March 31, 2017 | 22.39M |
| December 31, 2016 | 26.21M |
| September 30, 2016 | 24.86M |
| June 30, 2016 | 23.84M |
| March 31, 2016 | 19.25M |
| December 31, 2015 | 12.78M |
| September 30, 2015 | 14.70M |
| June 30, 2015 | 6.198M |
| March 31, 2015 | 6.198M |
| December 31, 2014 | 7.386M |
| September 30, 2014 | 5.694M |
| June 30, 2014 | 5.183M |
| March 31, 2014 | 7.637M |
| December 31, 2013 | 8.336M |
| September 30, 2013 | 6.584M |
| June 30, 2013 | 7.234M |
| March 31, 2013 | 5.939M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
7.467M
Minimum
Sep 2022
26.02M
Maximum
Jun 2021
14.44M
Average
13.24M
Median
Research and Development Expense (Quarterly) Benchmarks
| Nektar Therapeutics | 27.41M |
| Rigel Pharmaceuticals Inc | 6.026M |
| Vistagen Therapeutics Inc | 4.538M |
| Adverum Biotechnologies Inc | 15.41M |
| SeaStar Medical Holding Corp | 1.075M |